跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
WIXELA INHUB
Authorized
STANDARD
WIXELA INHUB
Mylan Pharmaceuticals ULC
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
855c5a8e6f24308f
Company
Mylan Pharmaceuticals ULC
Type
Standard
Approval Details
Approval Id
855c5a8e6f24308f
Drug Approval Canada Name
WIXELA INHUB
Product Name
WIXELA INHUB
Status
Marketed
Status Date
2020-02-13
Original Market Date
2020-02-13
Din
02495600
Drug Class
Human
Dosage Form
Powder
Route Of Administration
Inhalation
Schedule
Prescription
Ahfs
68:04.00
Atc Original
R03AK06 SALMETEROL AND FLUTICASONE
Atc Name
r 03 ak 06
Aig Number
0238341002
Company Name
Mylan Pharmaceuticals ULC
Company Address
85 Advance Road, Etobicoke, Ontario, Canada, M8Z 2S6
Active Ingredients
FLUTICASONE PROPIONATE
250 MCG / ACT
SALMETEROL (SALMETEROL XINAFOATE)
50 MCG / ACT
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
855c5a8e6f24308f
Type
Standard
Back to Health Canada Approvals
WIXELA INHUB - Health Canada Drug Approval Details